CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today that data from one of its lead oncology programs targeting SF3B1, found in multiple cancers, will be presented at the upcoming 2015 American Society of Hematology (ASH) Meeting and Exposition in Orlando, December 4-8, 2015. The poster presentation from Buonamici et al., (abstract 1643) will be take place Saturday, December 5, 2015, 5:30 – 7:30 p.m. https://ash.confex.com/ash/2015/webprogram/Paper84908.html
